During the Stifel 2026 Targeted Oncology Virtual Forum, Lynn Seely, the Principal Executive Officer and CEO of Lyell Immunopharma, provided insights into the company's innovative approach to cell therapy. Lyell Immunopharma specializes in next-generation cell therapies aimed at treating patients with hematologic malignancies and solid tumors. Seely highlighted two lead clinical programs: one targeting large B-cell lymphoma, which seeks to displace currently approved CD19 CAR therapies, a market estimated to be worth $3 billion. The second program involves a novel CAR therapy for metastatic colorectal cancer, showcasing Lyell's commitment to addressing significant medical needs in oncology. Notably, Lyell operates its own manufacturing facility, enhancing its ability to control production and launch processes. This unique aspect of their operations positions Lyell favorably in the competitive landscape of cell therapy.